Sign in now to see personalised content appear here.

You can also see your reading history and subscription details on your subscriber page.

Why subscribe?
Find out more.

Sign up for your FREE email newsletter  +


Off-Patent Drugs Bill could soon be back on track in UK

If draft legislation goes ahead, pharmaceutical companies will need to tread carefully, says IP law firm Withers & Rogers


Crescendo Biologics expands ADC programmes with Innovate UK grant

Award will support development of new therapies to target prostate cancer

Europe | R and D

Homing in on cancer targets

Traditional cancer treatments like chemo- and radiotherapy are blunt instruments. Dr Sarah Houlton looks at developments in CAR T-cell technology, which promises a much more precise approach

R and D | Therapeutic Sector

Novartis enters drug delivery collaboration with Rani Therapeutics

Will use Rani's proprietary oral biotherapeutics drug delivery platform to formulate and test selected biologics

Europe | North America | Drug Delivery | R and D

Strides to buy drug assets in Australia and Mauritius from Aspen for approximately US$300m

Part of aim to focus on areas where most value can be added, says Strides

Finance | Asia

Big data, big questions

Huge quantities of aggregated research and real-patient information may hold important keys for future drug discovery. Jaqui Hodgkinson, Elsevier R&D Solutions, looks at the benefits and challenges of harnessing meaningful information quickly and cost-effectively from big data

R and D | Information Technology

Biocon-Mylan programmes make progress

Partnership has a strong portfolio of generic insulin analogues and biosimilars including monoclonal antibodies (MAbs) and recombinant proteins at various stages of development

R and D | Biotechnology | Generics | Asia

Pioneering a path to precision oncology through NGS

Next-Generation Sequencing is revolutionising the study of genomics and molecular biology. Thermo Fisher Scientific explains how it can be used in the design of therapeutic products with a future goal of enabling precision oncology

R and D | Biotechnology | Therapeutic Sector | Measurement and Analysis

Chinese consortium to acquire US biotech Ambrx

Group comprises Fosun Pharma, HOPU Investments, CEL Healthcare Fund, and WuXi PharmaTech

North America | Biotechnology | Finance | Asia

Creating proactive productvigilance systems

In addition to proof of drug effectiveness, pharmacovigilance has become an important safety requirement laid down by the regulators. Dr Chitra Lele, CSO, Sciformix Corporation, discusses the importance of establishing an effective global safety framework to meet today’s needs

Manufacturing and Equipment

Initiating change in drug development and manufacture

With R&D and production costs spiralling and the growing regulatory requirements biting into the profit margins of drug sales, the industry needs radical change to manufacturing models, argues Ed Price, President, PCI Synthesis

North America | R and D | Manufacturing and Equipment